KPTI - Karyopharm Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

KPTI is currently covered by 5 analysts with an average price target of $4.11. This is a potential upside of $3.51 (585%) from yesterday's end of day stock price of $0.6.

Karyopharm Therapeutics's activity chart (see below) currently has 17 price targets and 38 ratings on display. The stock rating distribution of KPTI is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 21.99% with an average time for these price targets to be met of 84.73 days.

Highest price target for KPTI is $18, Lowest price target is $3, average price target is $4.11.

Most recent stock forecast was given by BRIAN ABRAHAMS from RBC on 10-Feb-2025. First documented stock forecast 02-Jun-2015.

Currently out of the existing stock ratings of KPTI, 24 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$3

$-8.59 (-74.12%)

$3

12 days ago
(10-Feb-2025)

1/9 (11.11%)

$-8.59 (-74.12%)

38

Buy

$18

$6.41 (55.31%)

$18

12 days ago
(10-Feb-2025)

0/8 (0%)

$6.41 (55.31%)

Buy

$7

$-4.59 (-39.60%)

$7

12 days ago
(10-Feb-2025)

0/4 (0%)

$-4.59 (-39.60%)

Buy

$5

$-6.59 (-56.86%)

$5

12 days ago
(10-Feb-2025)

1/3 (33.33%)

$-6.59 (-56.86%)

279

Hold

$4

$2.69 (205.34%)

$10

1 years 6 months 15 days ago
(07-Aug-2023)

6/11 (54.55%)

$2.39 (148.45%)

305

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is KPTI (Karyopharm Therapeutics) average time for price targets to be met?

On average it took 84.73 days on average for the stock forecasts to be realized with a an average price target met ratio 21.99

Which analyst has the current highest performing score on KPTI (Karyopharm Therapeutics) with a proven track record?

MICHAEL ULZ

Which analyst has the most public recommendations on KPTI (Karyopharm Therapeutics)?

Michael Ulz works at MORGAN STANLEY and has 4 price targets and 3 ratings on KPTI

Which analyst is the currently most bullish on KPTI (Karyopharm Therapeutics)?

Maury Raycroft with highest potential upside - $33.69

Which analyst is the currently most reserved on KPTI (Karyopharm Therapeutics)?

Brian Abrahams with lowest potential downside - -$8.59

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?